North Bay Business Journal

  • BioMarin begins phase 3 drug trial in Europe

    June 7th, 2011

    NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the start of phase 3 trial in Europe of a treatment for a rare immune system disease, Lambert-Eaton Myasthenic Syndrome, or LEMS.

  • TriVascular takes Ovation across Europe

    April 18th, 2011

    SANTA ROSA — TriVascular, maker of stent grafts for endovascular aneurysm repair (EVAR), is marching across Europe with its first product. The Ovation stent graft system was approved for sale overseas last year.

  • BioMarin starts pivotal clinical trial for GALNS treatment

    February 1st, 2011

    NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it started a phase 3 trial for N-acetylgalactosamine 6-sulfatase, named GALNS or BMN 110. It’s intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis type IVA, or MPS IVA, also called Morquio A syndrome.

  • St. Helena cancer center gets clinical trial approval

    October 9th, 2010

    ST. HELENA – The Martin-O’Neil Cancer Center at St. Helena Hospital has earned government approval to enroll patients in national clinical trials designed to improve outcomes and reduce side effects. According to center Medical Director Gregory Smith, the center now has access to large national clinical trials covering most types of cancer and can enroll a patient for treatment in as little as 24 hours. The trials are National Cancer Institutes approved, which means Medicare and most insurance companies cover them.

  • TriVascular trials progress in Europe

    March 29th, 2010

    SANTA ROSA — TriVascular’s abdominal stent graft is showing solid results in European clinical trials, well on its way to holding a leading position in a predicted $2 billion global market.

Site Index

Industry News
Events
Mobile

Tags